Morningstar

BioInvent Announces Publication of Preclinical and Early Phase 1 Data for BI-1607 in HER2-Positive Advanced Solid Tumors

BioInvent remains focused on BI-1206, its lead FcγRIIB‑blocking antibody, and BI-1808, its anti-TNFR2 antibody,and the BI‑1607 program is currently paused BioInvent International AB ("BioInvent") ...
Morningstar

EMA Positive Opinion for Orphan Drug Designation to BioInvent's BI‑1808 for the Treatment of Cutaneous T-cell Lymphoma

LUND, SE / ACCESS Newswire / November 17, 2025 / BioInvent International AB ("BioInvent")(Nasdaq Stockholm: BINV)(STO:BINV), a biotech company focused on the discovery and development of novel and ...
Finanznachrichten

BioInvent International: BioInvent Announces Publication of Preclinical and Early Phase 1 Data for BI-1607 in HER2-Positive Advanced Solid Tumors

LUND, SE / ACCESS Newswire / November 18, 2025 / BioInvent International (STO:BINV): Most (78%) patients experienced disease control (stable disease), including heavily pretreated individuals with ...